On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...

Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...

Pediatric sleep apnea is a sleep disorder that causes breathing pauses during sleep. The two main types of sleep apnea in children are obstructive sleep apnea, which is the most common and typically ...

Vivos Therapeutics, Inc. (VVOS) announced on Wednesday that it has obtained 510(k) clearance from the FDA for its DNA oral medical ...

The clinical syndrome of obstructive sleep apnea (OSAS) in children is a distinct, yet somewhat overlapping disorder with the condition that occurs in adults, such that the clinical manifestations ...

It is designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17. The Vivos device is intended for those diagnosed with snoring and/or OSA ...

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...

When evaluating autism and sleep, data shows that children with ASD exposed to ACEs experience shorter sleep duration than their peers.

The treatment of sleep disorders in India has evolved significantly over the years, transitioning from basic lifestyle advice ...